drugset / Trial / NCT06362967

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

NCT06362967

Phase 2 Recruiting 30 enrolled Anhui Provincial Hospital
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the efficacy and safety of immunoadsorption or plasma exchange combined with rituximab and high-dose IVIG to reduce high titres of anti-HLA antibodies in patients prior to allogeneic haematopoietic stem cell transplantation

Timeline

Start
2024-05-01
Primary completion
2026-12-31
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic
Subject Rituximab Monoclonal antibody